Cytosorbents Corp (CTSO) Shares Bought by EAM Investors LLC

EAM Investors LLC increased its holdings in Cytosorbents Corp (NASDAQ:CTSO) by 107.9% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 178,690 shares of the medical research company’s stock after purchasing an additional 92,723 shares during the period. EAM Investors LLC’s holdings in Cytosorbents were worth $2,037,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Commonwealth Equity Services LLC bought a new stake in Cytosorbents in the 2nd quarter worth about $199,000. Bradley Foster & Sargent Inc. CT bought a new stake in shares of Cytosorbents during the 2nd quarter valued at about $1,591,000. Pegasus Partners Ltd. bought a new stake in shares of Cytosorbents during the 2nd quarter valued at about $114,000. Ballentine Partners LLC bought a new stake in shares of Cytosorbents during the 2nd quarter valued at about $228,000. Finally, Millennium Management LLC grew its stake in shares of Cytosorbents by 134.4% during the 1st quarter. Millennium Management LLC now owns 384,330 shares of the medical research company’s stock valued at $2,710,000 after purchasing an additional 220,353 shares during the period. Institutional investors own 13.12% of the company’s stock.

In other news, CFO Kathleen P. Bloch sold 12,400 shares of Cytosorbents stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $9.00, for a total transaction of $111,600.00. Following the transaction, the chief financial officer now directly owns 265,704 shares of the company’s stock, valued at approximately $2,391,336. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Vincent Capponi sold 7,154 shares of Cytosorbents stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $9.00, for a total value of $64,386.00. Following the transaction, the chief operating officer now directly owns 321,551 shares in the company, valued at $2,893,959. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,989 shares of company stock worth $1,042,667. Insiders own 6.90% of the company’s stock.

Cytosorbents opened at $11.55 on Friday, Marketbeat reports. Cytosorbents Corp has a 52-week low of $4.50 and a 52-week high of $13.40. The company has a quick ratio of 8.60, a current ratio of 8.82 and a debt-to-equity ratio of 0.46.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, August 2nd. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.07). The firm had revenue of $5.76 million for the quarter, compared to the consensus estimate of $5.08 million. Cytosorbents had a negative net margin of 74.60% and a negative return on equity of 100.51%. equities research analysts forecast that Cytosorbents Corp will post -0.56 EPS for the current year.

A number of research firms have issued reports on CTSO. BidaskClub downgraded Cytosorbents from a “buy” rating to a “hold” rating in a research note on Friday. Maxim Group set a $12.00 price target on Cytosorbents and gave the company a “buy” rating in a research note on Tuesday, April 24th. Cowen restated a “buy” rating and set a $15.00 price target on shares of Cytosorbents in a research note on Friday, August 3rd. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Cytosorbents in a research note on Wednesday, May 9th. Finally, ValuEngine upgraded Cytosorbents from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $13.31.

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Featured Story: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Corp (NASDAQ:CTSO).

Institutional Ownership by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply